Jazz Pharmaceuticals (JAZZN) Stock Forecast & Price Target
JAZZN Analyst Ratings
Strong Buy
17Buy1Hold0Sell
Based on 18 analysts giving stock ratings to Jazz Pharmaceuticals in the past 3 months
JAZZN Stock 12 Month Forecast
Average Price Target
MXN 5,646.82▲(89.17% Upside)Based on 18 Wall Street analysts offering 12 month price targets for Jazz Pharmaceuticals in the last 3 months. The average price target is MXN 5,646.82 with a high forecast of MXN 6,363.29 and a low forecast of MXN 4,324.02. The average price target represents a 89.17% change from the last price of MXN 2,985.00.
Past 12 Months12 Month ForecastDec2025Sep2026
HighMXN 6.36K
AverageMXN 5.65K
LowMXN 4.32K
Highest Price TargetHighestMXN 6,363.29Average Price TargetMXN 5,646.82Lowest Price TargetLowestMXN 4,324.02
Detailed List of Analyst Forecasts
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Jessica Fye | J.P. Morgan | MXN 5,211.48→MXN 5,664.65 | buy | 89.77%Upside | Assigned | 10/28/26 | ||
| Ashwani Verma | UBS | MXN 6,363.29 | buy | 113.18%Upside | Reiterated | 10/28/26 | ||
| Geoff Meacham | Citi | MXN 6,136.71 | buy | 105.58%Upside | Reiterated | 10/27/26 | ||
| Sean Laaman | Morgan Stanley | MXN 6,080.06→MXN 5,929.00 | buy | 98.63%Upside | Assigned | 10/21/26 | ||
| Ami Fadia | Needham | MXN 5,853.47 | buy | 96.10%Upside | Reiterated | 10/16/26 | ||
| Etzer Darout | Barclays | MXN 5,117.07 | buy | 71.43%Upside | Reiterated | 10/13/26 | ||
| Jason Gerberry | Bank of America Securities | MXN 5,796.83→MXN 5,910.12 | buy | 97.99%Upside | Reiterated | 10/09/26 | ||
| Leonid Timashev | RBC Capital | MXN 5,645.77→MXN 5,589.12 | buy | 87.24%Upside | Reiterated | 10/08/26 | ||
| Gregory Renza | Truist Financial | MXN 5,305.89→MXN 5,400.30 | buy | 80.91%Upside | Reiterated | 10/07/26 | ||
| David Amsellem | Piper Sandler | MXN 5,853.47 | buy | 96.10%Upside | Reiterated | 09/28/26 | ||
| Jeffrey Walch | Bernstein | MXN 4,324.02 | hold | 44.86%Upside | Reiterated | 09/25/26 | ||
| Andrea Newkirk | Goldman Sachs | MXN 6,363.29 | buy | 113.18%Upside | Initiated | 09/24/26 | ||
| Joseph Thome | TD Cowen | MXN 5,664.65 | buy | 89.77%Upside | Reiterated | 08/31/26 | ||
| Gary Nachman | Canaccord Genuity | MXN 5,664.65 | buy | 89.77%Upside | Reiterated | 08/31/26 | ||
| David Hoang | Deutsche Bank | MXN 5,419.18→MXN 5,664.65 | buy | 89.77%Upside | Reiterated | 08/26/26 |
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Jessica Fye | 10/28/26 | MXN 5,211.48→MXN 5,664.65 | buy | 89.77%Upside | Assigned | J.P. Morgan | ||
| Ashwani Verma | 10/28/26 | MXN 6,363.29 | buy | 113.18%Upside | Reiterated | UBS | ||
| Geoff Meacham | 10/27/26 | MXN 6,136.71 | buy | 105.58%Upside | Reiterated | Citi | ||
| Sean Laaman | 10/21/26 | MXN 6,080.06→MXN 5,929.00 | buy | 98.63%Upside | Assigned | Morgan Stanley | ||
| Ami Fadia | 10/16/26 | MXN 5,853.47 | buy | 96.10%Upside | Reiterated | Needham | ||
| Etzer Darout | 10/13/26 | MXN 5,117.07 | buy | 71.43%Upside | Reiterated | Barclays | ||
| Jason Gerberry | 10/09/26 | MXN 5,796.83→MXN 5,910.12 | buy | 97.99%Upside | Reiterated | Bank of America Securities | ||
| Leonid Timashev | 10/08/26 | MXN 5,645.77→MXN 5,589.12 | buy | 87.24%Upside | Reiterated | RBC Capital | ||
| Gregory Renza | 10/07/26 | MXN 5,305.89→MXN 5,400.30 | buy | 80.91%Upside | Reiterated | Truist Financial | ||
| David Amsellem | 09/28/26 | MXN 5,853.47 | buy | 96.10%Upside | Reiterated | Piper Sandler | ||
| Jeffrey Walch | 09/25/26 | MXN 4,324.02 | hold | 44.86%Upside | Reiterated | Bernstein | ||
| Andrea Newkirk | 09/24/26 | MXN 6,363.29 | buy | 113.18%Upside | Initiated | Goldman Sachs | ||
| Joseph Thome | 08/31/26 | MXN 5,664.65 | buy | 89.77%Upside | Reiterated | TD Cowen | ||
| Gary Nachman | 08/31/26 | MXN 5,664.65 | buy | 89.77%Upside | Reiterated | Canaccord Genuity | ||
| David Hoang | 08/26/26 | MXN 5,419.18→MXN 5,664.65 | buy | 89.77%Upside | Reiterated | Deutsche Bank |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering Jazz Pharmaceuticals
3 Months
Success Rate13/21 ratings generated profit
62%
Average Return
+6.23%
Copying Joseph Thome's trades and holding each position for 3 Months would result in 61.90% of your transactions generating a profit, with an average return of +6.23% per trade.
1 Year
Success Rate17/21 ratings generated profit
81%
Average Return
+33.54%
Copying Joseph Thome's trades and holding each position for 1 Year would result in 80.95% of your transactions generating a profit, with an average return of +33.54% per trade.
2 Years
Success Rate18/21 ratings generated profit
86%
Average Return
+52.12%
Copying Joseph Thome's trades and holding each position for 2 Years would result in 85.71% of your transactions generating a profit, with an average return of +52.12% per trade.
JAZZN Analyst Recommendation Trends
| Rating | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 |
|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 3 |
| Buy | 31 | 35 | 54 | 50 | 48 |
| Hold | 4 | 4 | 2 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 35 | 39 | 56 | 51 | 52 |
In the current month, JAZZN has received 51 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. JAZZN average Analyst price target in the past 3 months is 5,646.82.
JAZZN Financial Forecast
HighMXN -45.99
ConsensusMXN -76.01
LowMXN -114.97
JAZZN Earnings Forecast
Next quarter’s earnings estimate for JAZZN is -MXN 76.01 with a range of -MXN 114.97 to -MXN 45.99. The previous quarter’s EPS was MXN 107.27. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
HighMXN 23.3B
ConsensusMXN 22.7B
LowMXN 22B
JAZZN Sales Forecast
Next quarter’s sales forecast for JAZZN is MXN 22.70B with a range of MXN 21.98B to MXN 23.34B. The previous quarter’s sales results were MXN 22.70B. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
JAZZN Stock Forecast FAQ
What is MX:JAZZN’s average 12-month price target, according to analysts?
Based on analyst ratings, Jazz Pharmaceuticals’s 12-month average price target is Mex$5,646.82.
What is MX:JAZZN’s upside potential, based on the analysts’ average price target?
Jazz Pharmaceuticals has 89.17% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Jazz Pharmaceuticals a Buy, Sell or Hold?
Jazz Pharmaceuticals has a consensus rating of Strong Buy, which is based on 17 buy ratings, 1 hold ratings and 0 sell ratings.
What is Jazz Pharmaceuticals’s share price target?
The average share price target for Jazz Pharmaceuticals is Mex$5,646.82. This is based on 18 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is Mex$6,363.29, and the lowest forecast is Mex$4,324.02. The average share price target represents a 89.17% increase from the current price of Mex$2,985.
What do analysts say about Jazz Pharmaceuticals?
Jazz Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 18 Wall Street analysts.
How can I buy shares of Jazz Pharmaceuticals?
To buy shares of MX:JAZZN, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.